Merck has inaugurated the Merck Global Capability Centre (MGCC) in Electronic City, Bengaluru. The new 17,000-square-metre campus integrates the company’s existing India technology and services ...

AI drug design specialist Protillion Biosciences has inked a $510 million biobucks collaboration and license agreement with Merck & Co., bringing together Protillion’s platform and Merck’s drug ...

Merck is planning further cuts at its headquarters in New Jersey as part of an ongoing restructuring effort. In a filing with the state Department of Labor & Workforce Development, the pharmaceutical ...

RAHWAY, N.J.- Merck is cutting dozens of jobs at its Rahway headquarters. According to a notice filed with New Jersey's Department of Labor, 88 employees are being laid off, effective September 4, ...

More biopharma layoffs are hitting New Jersey, this time from Merck & Co., in the latest phase of headcount reductions attributed to its $3 billion cost-cutting plan announced last July. The latest ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

NEW YORK, April 22 (Reuters) - Inhibrx Biosciences (INBX.O), opens new tab has drawn interest from drugmakers including Merck & Co (MRK.N), opens new tab, Germany’s Merck KGaA (MRCG.DE), opens new tab ...

Merck & Co. agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities. In a Worker Adjustment and Retraining Notification (WARN) Act alert filed ...

Merck on Tuesday revealed a lower-than-expected outlook for 2026 as the drugmaker aims to remake its business before its powerhouse cancer drug loses patent protection in a few years. The stock MRK ...